These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 2841483

  • 1. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB).
    Britt WJ, Vugler L, Stephens EB.
    J Virol; 1988 Sep; 62(9):3309-18. PubMed ID: 2841483
    [Abstract] [Full Text] [Related]

  • 2. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response.
    Britt WJ, Vugler L, Butfiloski EJ, Stephens EB.
    J Virol; 1990 Mar; 64(3):1079-85. PubMed ID: 2154594
    [Abstract] [Full Text] [Related]

  • 3. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z, Kaltcheva T, Iniguez A, Martinez J, La Rosa C, Wussow F, Diamond DJ.
    J Virol; 2018 Oct 01; 92(19):. PubMed ID: 30045984
    [Abstract] [Full Text] [Related]

  • 4. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.
    Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, Barrell B, Hart H, Bell SE, Minson AC.
    EMBO J; 1986 Nov 01; 5(11):3057-63. PubMed ID: 3024973
    [Abstract] [Full Text] [Related]

  • 5. Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.
    Cui X, Cao Z, Wang S, Lee RB, Wang X, Murata H, Adler SP, McVoy MA, Snapper CM.
    Vaccine; 2018 Sep 05; 36(37):5580-5590. PubMed ID: 30082162
    [Abstract] [Full Text] [Related]

  • 6. Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus.
    Rapp M, Messerle M, Bühler B, Tannheimer M, Keil GM, Koszinowski UH.
    J Virol; 1992 Jul 05; 66(7):4399-406. PubMed ID: 1318410
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells.
    Wells DE, Vugler LG, Britt WJ.
    J Gen Virol; 1990 Apr 05; 71 ( Pt 4)():873-80. PubMed ID: 2157800
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Little role of anti-gB antibodies in neutralizing activity of patient's sera with human cytomegalovirus (HCMV) infection.
    Park JW, Kim DJ, Kim J, Park CG, Hwang ES, Cha CY.
    J Korean Med Sci; 2000 Apr 05; 15(2):133-8. PubMed ID: 10803687
    [Abstract] [Full Text] [Related]

  • 13. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates.
    Shen S, Wang S, Britt WJ, Lu S.
    Vaccine; 2007 Apr 30; 25(17):3319-27. PubMed ID: 17287056
    [Abstract] [Full Text] [Related]

  • 14. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies.
    Marshall GS, Ricciardi RP, Rando RF, Puck J, Ge RW, Plotkin SA, Gönczöl E.
    J Infect Dis; 1990 Nov 30; 162(5):1177-81. PubMed ID: 2172396
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Structural and functional properties of the 14-kDa envelope protein of vaccinia virus synthesized in Escherichia coli.
    Lai CF, Gong SC, Esteban M.
    J Biol Chem; 1990 Dec 25; 265(36):22174-80. PubMed ID: 2266120
    [Abstract] [Full Text] [Related]

  • 17. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B.
    Navarro D, Lennette E, Tugizov S, Pereira L.
    J Med Virol; 1997 Aug 25; 52(4):451-9. PubMed ID: 9260696
    [Abstract] [Full Text] [Related]

  • 18. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.
    Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Méric C, Plotkin SA, Gönczöl E.
    Vaccine; 1999 Jan 25; 17(1):50-8. PubMed ID: 10078607
    [Abstract] [Full Text] [Related]

  • 19. Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate.
    Gönczöl E, Berensci K, Pincus S, Endresz V, Méric C, Paoletti E, Plotkin SA.
    Vaccine; 1995 Aug 25; 13(12):1080-5. PubMed ID: 7491815
    [Abstract] [Full Text] [Related]

  • 20. Molecular analysis of the immune response to human cytomegalovirus glycoprotein B (gB). II. Low gB-specific T and B cell responses are associated with expression of certain HLA-DR alleles.
    Curtsinger JM, Liu YN, Radeke R, Bryon MK, Fuad S, Bach FH, Gehrz RC.
    J Gen Virol; 1994 Feb 25; 75 ( Pt 2)():301-7. PubMed ID: 8113751
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.